We are live on ! Find out more

Axogen

AXGN

Market cap $2.89B

49.25 USD

+11.79

31.47%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

48.87

-0.38

0.77%

1 day

31.47%

5 days

35.01%

1 month

13.58%

3 months

19.68%

6 months

17.29%

Year to date

58.87%

1 year

172.4%

5 years

225.51%

10 years

453.37%

About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

Employees: 622

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35%

Neutral 60%

Negative 5%

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Zacks Investment Research

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

Axogen, Inc. Reports Third Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million

Axogen, Inc. Reports Third Quarter 2026 Financial Results

Zacks Investment Research

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

Zacks Investment Research

GMED or AXGN: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?

GMED or AXGN: Which Is the Better Value Stock Right Now?

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

ALACHUA, Fla. and TAMPA, Fla.

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Zacks Investment Research

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

ALACHUA, Fla. and TAMPA, Fla.

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

3 Emerging Biotech Stocks With Significant Upside Potential

Biotech and specialty health care stocks can be attractive speculations because product innovation can drive explosive growth and attract intense takeover interest from large pharmaceutical companies. The challenge is determining which ones justify the risk, because early-stage drug developers are numerous, and many remain cash-burning for years.

3 Emerging Biotech Stocks With Significant Upside Potential

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

See News Rankings

Price charts implemented using Lightweight Charts™